Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma
Epidermal growth factor receptor (EGFR) is highly overexpressed in malignant mesothelioma (MM). MAb806 is a novel anti-EGFR antibody that selectively targets a tumor-selective epitope. MAb806-derived antibody drug conjugates (ADCs), ABT-414, ABBV-221 and ABBV-322, may represent a novel therapeutic s...
Saved in:
Main Authors: | Puey-Ling Chia (Author), Sagun Parakh (Author), Ming-Sound Tsao (Author), Nhu-An Pham (Author), Hui K. Gan (Author), Diana Cao (Author), Ingrid J. G. Burvenich (Author), Angela Rigopoulos (Author), Edward B. Reilly (Author), Thomas John (Author), Andrew M. Scott (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2020-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Homogeneous antibody-drug conjugates: DAR 2 anti-HER2 obtained by conjugation on isolated light chain followed by mAb assembly
by: Mercè Farràs, et al.
Published: (2020) -
Malignant Mesothelioma
Published: (2012) -
Malignant Mesothelioma
Published: (2021) -
Antibody-drug conjugates: beyond current approvals and potential future strategies
by: Siddharth Menon, et al.
Published: (2022) -
Tanezumab: a selective humanized mAb for chronic lower back pain
by: Webb MP, et al.
Published: (2018)